Vincent-Philippe Lavalle

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1961899/vincent-philippe-lavallee-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31	811	16	28
papers	citations	h-index	g-index
37 ext. papers	1,197 ext. citations	8.3 avg, IF	3.63 L-index

#	Paper	IF	Citations
31	High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. <i>Blood</i> , 2020 , 135, 1882-1886	2.2	19
30	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. <i>Nature Medicine</i> , 2020 , 26, 259-269	50.5	127
29	Genetic characterization of ABT-199 sensitivity in human AML. <i>Leukemia</i> , 2020 , 34, 63-74	10.7	26
28	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019 , 134, 263-276	2.2	23
27	Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2019 , 36, 84-99.e8	24.3	75
26	Targeted variant detection using unaligned RNA-Seq reads. Life Science Alliance, 2019, 2,	5.8	5
25	Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 1934-1943	10.7	26
24	Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. <i>Blood Advances</i> , 2019 , 3, 552-563	7.8	14
23	Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. <i>Leukemia</i> , 2018 , 32, 1349-1357	10.7	17
22	MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2018 , 8, 478-497	24.4	37
21	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018 , 8, 68	7	23
20	Chemogenomic Profiling of Complex Karyotype AML Reveals a Novel Susceptibility to G2/M Checkpoint Inhibition Mediated By HMGA2 Overexpression. <i>Blood</i> , 2018 , 132, 3925-3925	2.2	1
19	Genetic Characterization of ABT-199 Sensitivity in Human AML. <i>Blood</i> , 2018 , 132, 283-283	2.2	1
18	Chemogenomic Approach Unveils the Increased Susceptibility of RUNX1-Mutated AML to Glucocorticoids. <i>Blood</i> , 2018 , 132, 4675-4675	2.2	
17	Comprehensive Single-Cell RNA-Sequencing Mapping of Primary Acute Myeloid Leukemias and Profiling of NPM1-Mutated Cells. <i>Blood</i> , 2018 , 132, 995-995	2.2	1
16	MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. <i>Nucleic Acids Research</i> , 2017 , 45, e122	20.1	12
15	Chemogenomic Landscape of -mutated AML Reveals Importance of Allele Dosage in Genetics and Glucocorticoid Sensitivity. <i>Clinical Cancer Research</i> , 2017 , 23, 6969-6981	12.9	26

LIST OF PUBLICATIONS

14	mutations promote context-dependent transformation in acute myeloid leukemia with alterations. <i>Blood</i> , 2017 , 130, 2204-2214	2.2	38
13	GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. <i>Blood</i> , 2016 , 127, 2018-27	2.2	95
12	RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. <i>Blood</i> , 2016 , 127, 2498-501	2.2	46
11	Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. <i>Blood</i> , 2016 , 127, 3054-61	2.2	55
10	Chemo-Transcriptomic Analysis of Complex Karyotype AML Reveals Increased Expression of Cell Cycle Components and Exquisite Dependency on Polo-like Kinase 1. <i>Blood</i> , 2016 , 128, 769-769	2.2	1
9	Transcriptional Landscape of APL Identifies Aberrant Podoplanin Expression As a Defining Feature and Missing Link for the Bleeding Disorder of This Disease. <i>Blood</i> , 2016 , 128, 1075-1075	2.2	
8	The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. <i>Nature Genetics</i> , 2015 , 47, 1030-7	36.3	95
7	EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. <i>Blood</i> , 2015 , 125, 140-3	2.2	43
6	Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3855-3855	2.2	2
5	Mutational and Transcriptomic Landscape of AML with Core-Binding Factor Rearrangements. <i>Blood</i> , 2015 , 126, 802-802	2.2	
4	Prospective Evaluation of Fetal Haemoglobin Induction in Maternal Erythrocytes: A Preliminary Analysis of a Cohort of 345 Parturients. <i>Blood</i> , 2015 , 126, 3370-3370	2.2	
3	The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 1859-1859	2.2	
2	NGS-Based Detection Of Multiple RAS-Mutated Clones In MLL-Rearranged Leukemias Suggests Strong Oncogenic Collaboration. <i>Blood</i> , 2013 , 122, 744-744	2.2	
1	Target variant detection in leukemia using unaligned RNA-Seq reads		2